ClinicalTrials.gg
CompletedNCT04107688Updated May 14, 2024

Taste Perception, Salivary Proteins & the Oral Microbiome

An interventional study of Control and CPE in Saliva Altered and Taste, Altered, sponsored by Rutgers University. Completed at 1 site in United States. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-05-14.

Sponsored by Rutgers University · Not applicable, Interventional, and Basic science

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Non-randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

Genetic differences in taste are believed to play an important role in food selection, especially for strong-tasting foods and beverages. The overall goal of this project is to better understand how genes that control food preferences differ among people and whether saliva composition and oral health are related to these differences.

This study examines the effects of a daily cranberry extract oral rinse on salivary protein responses and the oral microbiome (as a proxy measure of oral health). The study will be conducted in healthy adults who are presumably at high-risk (non-tasters of PROP; homozygous recessive for tas2R38 gene) or low-risk (super-taster of PROP; homozygous dominant for tas2R38 gene) of oral disease.

The specific aims are to determine if the use of cranberry polyphenol extract rinse will:

  1. alter the oral microbial profile
  2. induce changes in the salivary protein response
  3. be associated with changes in taste and flavor perception

Participants will be screened for good overall and oral health (see inclusion/exclusion criteria below). Each subject's period of participation will be 2 weeks. Days 1-3 of the study is a run-in period. Subjects rinse with spring water 2-times/day (after brushing their teeth in the morning and evening). During days 4-14, subjects will rinse in a similar manner with a solution of cranberry-derived polyphenol extract (CPE) in spring water. Saliva will be collected from subjects in a brief session (10 min) on Days 3 and Day 14. Saliva samples will be analyzed for salivary proteins and microbial profile analysis. The purpose of this analysis is to measure the relative ratios of beneficial vs. disease-causing microbes in the mouth using 16S RNA sequencing. On each of the testing days, subjects will also evaluate food samples for standard taste and flavor attributes.

02

Conditions studied

  • Saliva Altered
  • Taste, Altered

Browse trials for

Keywords

  • Oral Microbiome
03

In context

Dysgeusia

52 studies on the registry are indexed under Dysgeusia; 12 are open to participants now.

This study's enrollment of 20 is below the median of 49 across 28 interventional studies indexed under Dysgeusia.

Browse Dysgeusia studies →

Lead sponsor

Rutgers University is the lead sponsor of 28 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • PROP insensitive individuals (PROP non-tasters; homozygous recessive for tas2R38 gene)
  • PROP high-sensitive individuals (PROP super-tasters; homozygous dominant for tas2R38 gene)
  • Overall healthy; good oral health and hygiene routine
  • Current on a routine checkup by a oral/dental health professional
  • Recently underwent dental/cleaning by a oral/dental health professional
  • No ongoing oral health problems
  • Agree to use intervention material as prescribed
  • Agree to refrain from using any other oral rinse material during the term of the study

Exclusion criteria

Exclusion Criteria:

  • PROP medium-taster individuals (heterozygous for tas2R38 gene)
  • Taste or smell dysfunction
  • Pregnant or nursing
  • Oral piercings
  • Smoking
  • Use of medications other than
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    PROP non-taster subjects

    This arm will comprise of PROP non-taster subjects. Subjects will use a cranberry-derived oral rinse twice a day for 11 days following a 3-day control-rinse period.

    Other: Control · Other: CPE

  • Experimental
    PROP super-taster subjects

    This arm will comprise of PROP super-taster subjects. Subjects will use a cranberry-derived oral rinse twice a day for 11 days following a 3-day control-rinse period.

    Other: Control · Other: CPE

Interventions

  • OtherControl

    Subjects will use plain water as an oral rinse twice a day for 3 days.

  • OtherCPE

    Subjects will use a cranberry-derived oral rinse twice a day for 11 days.

06

What researchers measure

Primary outcomes

  1. Taste and Flavor Intensity Ratings

    Taste and Flavor intensity ratings of cranberry juice samples will be collected 3 days after control intervention and then at the end of the experimental intervention. An end-anchored (None, Very Strong) 15 cm line scale will be used with taste and key flavor attributes.

    Time frame: 3 days after control intervention; 11 days after experimental intervention

  2. Levels of Salivary Proteins

    Saliva will be collected 3 days after control intervention and then at the end of the experimental intervention. Samples will be analyzed via LCMS to establish proteomic composition before and after the intervention. Specifically, area of the ion current peaks (XIC peaks) generated will be used as a relative quantity of the salivary protein levels. The XIC peaks are proportional to the concentration of salivary proteins under constant conditions and will be used to understand the effect of the intervention on salivary protein levels.

    Time frame: 3 days after control intervention; 11 days after experimental intervention

  3. Composition of Oral Microbiome

    Salivary samples will be collected 3 days after control intervention and then at the end of the experimental intervention. Samples will be analyzed for microbial composition via 16S rRNA sequencing and data used to understand changes in microbial diversity before and after the intervention. Specifically operational taxonomic units will be identified and classified at the genera level.

    Time frame: 3 days after control intervention; 11 days after experimental intervention

07

Study locations

1 site
  • Rutgers University, Department of Food Science
    New Brunswick, New Jersey 08901, United States
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2019 to primary completion in Apr 2019, 0 months.

Of 18 interventional studies with no phase under Dysgeusia, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 16. This study's 0 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 25, 2019
First posted
Sep 27, 2019
StartActual
Mar 25, 2019
Primary completionActual
Apr 19, 2019
CompletionActual
Apr 19, 2019
Last update
May 14, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 14, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04107688
Lead sponsor
Rutgers University
Responsible party
Beverly J Tepper, Ph.D. (Professor, Rutgers University) — Principal investigator
First posted
Sep 27, 2019
Start date
Mar 25, 2019
Primary completion
Apr 19, 2019
Completion
Apr 19, 2019
Last update
May 14, 2024

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion